Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Glioblastoma

• The Safety and Effectiveness of NV-A01 in Glioma Patients
• Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
• Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma
• Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
• Lerapolturev (PVSRIPO) in GBM
• Study of Olutasidenib and Temozolomide in HGG
• T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
• Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
• Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
• A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
• A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
• A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
• Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
• A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
• N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
• Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
• A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
• Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
• Azeliragon in MGMT Unmethylated Glioblastoma
• A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
• Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
• Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
• Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors
• Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
• Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
• Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
• Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
• WP1066 and Radiation Therapy in Newly Diagnosed Glioblastoma Patients
• Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
• The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Recurrent or Progressed Following Treatment
• Study of Ribociclib and Everolimus in HGG and DIPG
• Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
• B7-H3-CAR T Cells for Pediatric CNS Tumors
• B-amyloid as a Marker for GBM Bioimaging
• Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
• A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma
• Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
• Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
• Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma
• Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Temozolomide in Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM)
• Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
• A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
• A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
• Dose Finding Study of [177Lu]Lu-NeoB in Combination With RT and TMZ in Newly Diagnosed GBM.
• Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab
• D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
• Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
• Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
• A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
• Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
• Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma
• Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed o6-methylguanine-DNA-methyltransferase (MGMT) Negative Glioblastoma Multiforme (GBM)
• Venous Thromboembolism Prevention in Outpatients With Glioma
• Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
• Glutamate Inhibitors in Glioblastoma
• LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
• CARv3-TEAM-E T Cells in Glioblastoma
• Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
• Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
• ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
• 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
• A Phase 2 Study of Methimazole in Patients With Progressive Glioblastoma
• A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
• Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
• Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme
• 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
• Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma
• RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
• Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
• A Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
• Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
• Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
• First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
• A Phase I Clinical Trial of Bevacizumab Injection
• B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
• Surgical Pembro +/- Olaparib w TMZ for rGBM
• 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
• Phase 2 Study of CAN008 in Newly Diagnosed GBM
• Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
• Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
• GBM Personalized Trial
• Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
• Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
• Combination Drug Therapy for Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
• A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of BI 907828 That Could be Tolerated in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
• Phase I Study of Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
• Tofacitinib in Recurrent GBM Patients
• A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
• Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
• PARP Inhibition for Gliomas (PI-4G or π4g)
• Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
• Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
• Study of BDTX-1535, in Participants With Glioblastoma or Non-Small Cell Lung Cancer
• Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
• The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
• Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
• A Phase 1 Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
• Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma
• GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
• Chlorpromazine and Standard of Care in Glioblastoma
• A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
• Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
• Phase 0 Plus Expansion Study of AZD1390 in Recurrent GBM Patients
• Trial of Dichloroacetate in Glioblastoma
• CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
• Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
• Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
• A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
• Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma and H3 K27M-Mutant High-Grade Glioma
• Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
• A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)
• Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
• Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
• A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
• Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
• A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
• hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
• Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma
• Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
• Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
• Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
• Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
• Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
• Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
• A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM
• Newly Diagnosed Glioblastoma
• Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)
• Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
• The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
• Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
• CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
• Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
• Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
• Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
• Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
• Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma
• A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
• AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
• MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
• Neuro-pharmacological Study of Ketoconazole for High-grade Gliomas
• Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
• ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
• Sonodynamic Therapy With ExAblate System in Glioblastoma Patients
• Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
• Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
• ASP8374 + Cemiplimab in Recurrent Glioma
• Neuro-pharmacological Study of Posaconazole for High-grade Gliomas: A Phase 0 Clinical Trial
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
• Chloroquine for Glioblastoma.
• Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
• A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
• Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
• A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
• Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
• Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
• ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)
• Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
• Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
• Niraparib Combined With Radiotherapy in rGBM
• Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
• A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging
• Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
• A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
• Study of Niacin in Glioblastoma
• Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
• Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
• AB154 Combined With AB122 for Recurrent Glioblastoma
• Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
• A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
• Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
• Study of Pamiparib in Newly Diagnosed and rGBM
• Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.
• Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
• Surgical Nivolumab And Ipilimumab For Recurrent GBM
• A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
• Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
• ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
• Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
• Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
• A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
• Sacituzumab Govitecan in Recurrent Glioblastoma
• Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
• A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
• Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
• Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma
• Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
• A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma - the ImmuneSense Study
• HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
• Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma
• Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
• Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
• Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
• Trial of AEO in New Glioblastoma (GBM)
• Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
• Evaluation of GLR2007 for Advanced Solid Tumors
• Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
• Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
• Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
• Infigratinib in Recurrent High-Grade Glioma Patients
• A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
• Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
• VB-111 in Surgically Accessible Recurrent/Progressive GBM
• Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
• LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
• Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
• Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
• Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
• Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
• NG101m Adjuvant Therapy in Glioblastoma Patients
• A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
• A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
• Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
• Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
• Comparison of Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumors Resection
• INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
• Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
• Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas
• Restrictive Use of Dexamethasone in Glioblastoma
• 2-OHOA With RT and TMZ for Adults With Glioblastoma
• Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
• Repurposing Chlorpromazine in the Treatment of Glioblastoma
• Niraparib/TTFields in GBM
• A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma
• Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
• Neoadjuvant Chemoradiation for Resectable Glioblastoma
• Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma
• Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
• WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
• Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
• Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
• Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
• Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
• Abemaciclib + Pembrolizumab In Glioblastoma
• A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
• Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
• Non-Viral TCR Gene Therapy
• Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
• B7-H3 CAR-T for Recurrent or Refractory Glioblastoma
• Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
• Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
• Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
• Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
• Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
• Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
• Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
• Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
• Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
• Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
• Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
• Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
• [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
• Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
• Pediatric Long-Term Follow-up and Rollover Study
• Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
• Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
• AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
• Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
• Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study
• Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
• BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
• Pembrolizumab for Newly Diagnosed Glioblastoma
• PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
• Fimepinostat in Treating Brain Tumors in Children and Young Adults
• Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
• Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
• Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
• A Study to Evaluate the Safety of 2-OHOA Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
• A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
• NVX-108 Combined With Radiation & TMZ, and During Maintenance Phase for Newly-diagnosed Glioblastoma Multiforme
• Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
• TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
• A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
• Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
• TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
• 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
• A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
• BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
• To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
• Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
• Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9
• Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
• A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
• 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma
• Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
• TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
• DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
• Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
• Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
• DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
• A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
• A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
• Feasibility of Individualized Therapy for Recurrent GBM
• Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
• 9-ING-41 in Patients With Advanced Cancers
• A Trial of Ipatasertib in Combination With Atezolizumab
• Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
• Treatment Intensification With Temozolomide in Adults With a Glioblastoma
• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
• A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
• Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
• Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17)
• A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
• Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
• Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
• Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
• Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
• GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
• A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
• HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
• Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
• HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
• OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
• Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
• Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
• [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
• Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
• INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
• TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
• Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
• Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
• Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
• INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
• Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)
• Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
• Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
• Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
• Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
• ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
• Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
• Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
• Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
• A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
• A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
• Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
• UNITE Study: Understanding New Interventions With GBM ThErapy
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
• Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
• Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma
• Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
• Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
• Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
• A Trial of KB004 in Patients With Glioblastoma
• Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
• Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
• Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
• Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme
• A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
• Phase I EGFR BATs in Newly Diagnosed Glioblastoma
• Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
• Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
• Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme
• Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
• Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
• 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme
• Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
• Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
• Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
• Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
• Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
• Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
• International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
• Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma
• NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
• HMPL-813 in Treating Patients With Glioblastoma
• Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma
• Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
• HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
• Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• NCT Neuro Master Match - N²M² (NOA-20)
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
• Bioavailability of Disulfiram and Metformin in Glioblastomas
• A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
• VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
• A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
• Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
• Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
• BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
• A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
• Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
• INtraoperative photoDYnamic Therapy of GliOblastoma
• Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
• Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
• Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
• A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
• Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
• BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
• NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
• Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
• Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
• A Study of Abemaciclib in Recurrent Glioblastoma
• INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
• A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• uPAR-PET/MRI in Glioblastoma Multiforme
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
• Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
• Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
• Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
• Regorafenib in Relapsed Glioblastoma
• IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma
• Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
• Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status
• Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
• Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma
• Feasibility Study on LITT for Newly Diagnosed Glioblastoma
• Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
• RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
• A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
• A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
• Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
• Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
• Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
• A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
• A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
• Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
• Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
• Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
• Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
• Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients
• A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
• Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
• Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
• Temozolomide Chronotherapy for High Grade Glioma
• Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
• A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
• Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
• A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
• Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
• Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
• A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
• A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
• Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
• Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
• VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
• Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
• Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
• Safety and Efficacy Study in Recurrent Grade IV Glioma
• Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
• Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
• Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
• Disulfiram in Recurrent Glioblastoma
• Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
• An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
• Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
• TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
• Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
• Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
• Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
• Cancer Stem Cell High-Throughput Drug Screening Study
• Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
• Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
• Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
• Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
• A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas
• Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
• The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
• mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
• An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
• Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
• Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
• Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
• Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery
• Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
• A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
• Neoadjuvant Nivolumab in Glioblastoma
• Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
• Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
• Nivolumab With DC Vaccines for Recurrent Brain Tumors
• Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma
• Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients
• A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
• Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
• A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
• Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
• Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
• qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.
• Ceritinib Rare Indications Study in ALK+ Tumors
• Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
• SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
• The Addition of Chloroquine to Chemoradiation for Glioblastoma,
• Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
• The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
• 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
• Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
• Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
• INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
• Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
• The Addition of Chloroquine to Chemoradiation for Glioblastoma
• Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
• Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
• DC Migration Study for Newly-Diagnosed GBM
• A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
• Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
• Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
• NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
• Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma
• A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
• Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
• TH-302 in Combination With Bevacizumab for Glioblastoma
• Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
• Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
• Pembrolizumab +/- Bevacizumab for Recurrent GBM
• Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
• A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
• Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
• A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
• Image-derived Prediction of Response to Chemo-radiation in Glioblastoma
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
• Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
• A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
• Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
• Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
• Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
• Safety of BBB Opening With the SonoCloud
• Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Prevention of Thrombocytopenia in Glioblastoma Patients
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
• Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
• TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
• DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
• Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
• Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
• 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
• Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
• A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
• MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
• Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
• Preoperative Chemoradiation for Glioblastoma
• Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
• FMISO PET Study of Glioblastoma
• Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
• Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
• Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
• Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
• Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
• A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
• Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
• Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
• A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
• Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
• Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
• Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
• Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
• 3T MRI Biomarkers of Glioma Treatment Response
• An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
• Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
• Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
• A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
• Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
• A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
• Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
• ANG1005 in Patients With Recurrent High-Grade Glioma
• Phase I Study of Safety and Immunogenicity of ADU-623
• Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
• Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
• Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
• A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
• STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
• ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
• Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
• Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
• Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
• Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
• Valproic Acid in Childhood Progressive Brain Tumors
• A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
• BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
• MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
• Tivozanib for Recurrent Glioblastoma
• A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
• Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
• Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
• Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
• A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
• Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
• Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
• Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
• A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
• A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
• Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
• MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS
• Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
• Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
• A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
• Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
• Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
• TRC105 for Recurrent Glioblastoma
• Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
• A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
• FET-PET for Evaluation of Response of Recurrent GBM to Avastin
• Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
• A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
• Bevacizumab Beyond Progression (BBP)
• Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
• Procarbazine and Lomustine in Recurrent Glioblastoma
• A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
• Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
• Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
• Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
• NOA-12: BIBF1120 and R-RT in Glioblastoma
• Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
• Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
• Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
• A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)
• Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
• A Study in Recurrent Glioblastoma (GB)
• Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
• Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
• Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
• Study of DC Vaccination Against Glioblastoma
• A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
• A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
• Cilengitide Imaging Trial in Glioblastoma
• A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
• PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
• Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
• PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
• Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
• Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
• Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
• Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
• Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
• AMG 595 First-in-Human in Recurrent Gliomas
• A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
• A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
• Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
• AZD7451 for Recurrent Gliomas
• Low Dose Radiation Therapy for Glioblastoma Multiforme
• Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
• More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
• Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
• A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
• Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
• A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and
• Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
• Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
• PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
• HYPAZ: Hypertension Induced by Pazopanib
• Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
• Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
• Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
• BIBF 1120 for Recurrent High-Grade Gliomas
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
• Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
• A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
• Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
• A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
• Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients
• Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
• Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
• Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
• Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
• Bosutinib in Adult Patients With Recurrent Glioblastoma
• Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas
• Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
• AZD8055 for Adults With Recurrent Gliomas
• Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
• Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
• A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
• Metronomic Temozolamide in Patients With Recurrent Glioblastoma
• Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
• Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
• Bevacizumab and Lomustine for Recurrent GBM
• Amgen 386 for Recurrent Glioblastoma
• Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
• Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
• BG & TMZ Therapy of Glioblastoma Multiforme
• RO4929097 in Treating Patients With Recurrent Invasive Gliomas
• A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
• Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
• Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
• Memantine for Recurrent Glioblastoma
• A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
• BIBF 1120 in Recurrent Glioblastoma Multiforme
• Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
• Temozolomide in Elderly Patients With KPS < 70
• Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
• Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
• Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme
• A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
• Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Dendritic Cell Cancer Vaccine for High-grade Glioma
• Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
• SCH-900105 in Recurrent Glioblastoma
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
• Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
• Vitamin D for Treatment of Glioblastoma Multiforme
• Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
• Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
• Effects of Steroid Tapering on Functional Capacity and Neurocognition
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
• A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
• Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
• Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
• Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
• Cellular Immunotherapy Study for Brain Cancer
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
• Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
• Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
• A Panobinostat Presurgery
• TPI 287 in Patients With Recurrent Glioblastoma Multiforme
• AMG 102 and Avastin for Recurrent Malignant Glioma
• PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
• Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
• Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
• Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastom
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
• Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma
• Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
• Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
• Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)
• Radiosurgery Plus Bevacizumab in Glioblastoma
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
• APG101 in Glioblastoma
• Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
• Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
• A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
• Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
• Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults
• Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
• Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma
• A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
• Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
• A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
• Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
• GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
• Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
• Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
• Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
• A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
• Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
• Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
• Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
• Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
• Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma
• A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
• Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
• Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
• Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
• Sunitinib to Treat Recurrent Brain Cancer
• A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
• Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme
• Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
• Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
• Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
• Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
• MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
• Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
• Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
• Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
• Sorafenib in Newly Diagnosed High Grade Glioma
• Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
• Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
• ADV-TK Improves Outcome of Recurrent High-Grade Glioma
• Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma
• Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
• Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
• Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
• Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
• Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)
• Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
• Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
• RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
• A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme
• Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
• A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma
• Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
• Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
• ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
• A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
• Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
• MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma
• Nimotuzumab in Adults With Glioblastoma Multiforma
• Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
• Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
• A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
• Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
• Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
• Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
• Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma
• Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
• Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
• A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
• Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
• Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
• Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
• Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
• Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
• A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
• Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
• Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
• O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
• Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
• Dose-Intense Temozolomide in Recurrent Glioblastoma
• Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
• Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
• Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
• Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
• Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
• Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
• Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
• Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
• Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
• Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
• Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
• Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
• Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
• Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
• Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
• Ph I SU011248 + Irinotecan in Treatment of Pts w MG
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
• Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
• Ph I Dasatinib + Erlotinib in Recurrent MG
• A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
• Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
• Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
• Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
• Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
• Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)
• Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
• A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
• Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
• CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
• Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
• Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
• Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• The Safety and Efficacy of DCA for the Treatment of Brain Cancer
• SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
• Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
• Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
• Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
• Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
• Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
• Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM
• 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
• Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
• Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
• Sunitinib in Treating Patients With Recurrent Malignant Gliomas
• Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
• Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
• Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
• A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
• Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
• Pazopanib in Treating Patients With Recurrent Glioblastoma
• Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
• Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
• O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
• Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
• Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
• Radiotherapy for Malignant Astrocytomas in the Elderly
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
• Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
• Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
• Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
• Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
• Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
• Epothilone in Recurrent Glioblastoma Patients
• AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
• The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
• Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
• Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
• PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
• Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
• Radiation Boost for Newly Diagnosed Glioblastoma Multiforme
• Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
• Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
• A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
• A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
• Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
• Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
• Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
• Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
• Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
• Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
• Enzastaurin Versus Lomustine in Glioblastoma
• Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
• Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
• Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
• Safety and Efficacy of Talampanel in Glioblastoma Multiforme
• Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
• Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
• Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
• A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
• Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
• Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
• Chloroquine for Treatment of Glioblastoma Multiforme
• Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
• Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
• Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
• Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
• Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
• Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
• ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
• Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
• 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
• Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
• Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
• GW572016 to Treat Recurrent Malignant Brain Tumors
• Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
• Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
• Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
• Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
• Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
• Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
• Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
• Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
• FR901228 in Treating Patients With Recurrent High-Grade Gliomas
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
• High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
• The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
• Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
• Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
• Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
• Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
• Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
• Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
• Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
• Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
• Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
• Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
• Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Sirolimus in Treating Patients With Glioblastoma Multiforme
• Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
• A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
• Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
• Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
• Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
• Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
• Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
• Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
• Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
• Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
• Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
• Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
• Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
• Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
• Radiation Therapy in Treating Patients With Glioblastoma
• S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
• ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
• CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
• Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
• Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
• Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme
• Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
• Bortezomib in Treating Patients With Recurrent Glioma
• Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme
• Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
• Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme
• Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
• Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
• Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
• Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
• Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
• Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
• Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
• Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
• Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
• Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
• Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
• Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
• Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
• Biological Therapy in Treating Patients With Glioblastoma Multiforme
• Combination Chemotherapy for Patients With Brain Cancer
• Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors
• Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme